-

Incyte to Report Fourth Quarter and Year-End Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2019 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 13, 2020.

The schedule for the press release and conference call/webcast is as follows:

  • Q4 & YE 2019 Press Release:

February 13, 2020 at 7:00 a.m. ET

  • Q4 & YE 2019 Conference Call:

February 13, 2020 at 8:00 a.m. ET

  • Domestic Dial-In Number:

877-407-3042

  • International Dial-In Number:

201-389-0864

  • Conference ID Number:

13698234

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13698234.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Incyte Contacts
Media
Catalina Loveman +1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil +1 302 498 5914
mbooth@incyte.com

Incyte

NASDAQ:INCY

Release Versions

Contacts

Incyte Contacts
Media
Catalina Loveman +1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil +1 302 498 5914
mbooth@incyte.com

More News From Incyte

Incyte Announces Change to its Board of Directors

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Change to its Board of Directors...

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

WILMINGTON, Del.--(BUSINESS WIRE)--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET...

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025...
Back to Newsroom